Abstract
Merck has submitted its second generation statistical computer assisted new drug application (CANDA) to the Food and Drug Administration (FDA). Continued development at Merck of the CANDA focused on the implementation of advanced features, analysis and implementation of a new hardware platform, and the initial incorporation of the CANDA as an internal new drug application (NDA) development tool.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
